The CPT code for an Exparel injection is 77002 [1].
What is Exparel and how is it used?
Exparel is an injectable medication used for post-operative pain management [2]. It is a long-acting local anesthetic that, once injected, releases the active ingredient, bupivacaine, over an extended period [3]. This sustained release aims to provide pain relief for 72 hours or longer after a surgical procedure, potentially reducing the need for opioid pain medications [4]. Exparel is administered by a healthcare professional directly into the surgical site or surrounding tissue [3].
What are the typical CPT codes associated with Exparel administration?
The primary CPT code for the administration of Exparel is 77002, which represents fluoroscopic guidance for needle placement [1]. In addition to the administration code, other CPT codes may apply depending on the specific surgical procedure being performed and the anesthesia used [5]. These could include codes for the surgical procedure itself and codes for anesthesia services, such as general anesthesia or regional blocks. It is essential for healthcare providers to correctly identify and bill all applicable codes to ensure proper reimbursement [5].
What factors influence the CPT coding for Exparel injections?
CPT coding for Exparel injections is influenced by several factors, including the location of the injection, the surgical procedure being performed, and the type of imaging guidance used. Code 77002 is specifically for fluoroscopic guidance [1]. If other imaging modalities like ultrasound are used, a different code might be applicable. Furthermore, the complexity of the surgical site and the total anesthesia time can also affect the overall billing [5]. Accurate documentation by the healthcare provider is crucial for correct coding and billing.
When does the patent for Exparel expire?
The primary patent for Exparel, U.S. Patent No. 8,841,315, was set to expire in 2026 [6]. However, there have been ongoing legal challenges and patent litigations related to Exparel, which could potentially affect its market exclusivity [7]. DrugPatentWatch.com tracks these patent statuses and provides detailed information on patent expirations and any associated legal disputes [6].
What are the potential competitors or alternatives to Exparel?
Alternatives to Exparel for post-operative pain management include traditional local anesthetics, opioid analgesics, and other non-opioid pain relievers [8]. Longer-acting local anesthetics are also emerging as potential competitors. The choice of pain management strategy often depends on the type of surgery, patient factors, and physician preference.
What are the risks and side effects associated with Exparel?
Like any medication, Exparel carries potential risks and side effects. Common side effects include nausea, constipation, headache, fever, and fatigue [3]. More serious risks, though less common, can include severe allergic reactions, nerve damage, and issues related to the specific surgical site. Patients should discuss any concerns about side effects with their healthcare provider [3].
How does Exparel compare to other pain management options?
Exparel offers a distinct advantage in providing prolonged post-operative pain relief, potentially reducing the reliance on opioids and their associated risks, such as addiction and respiratory depression [4]. While traditional local anesthetics provide immediate pain relief, their effect is short-lived. Opioids are effective for pain management but come with a higher risk of side effects and dependence [8].
---
Sources
[1] American Medical Association. CPT codes.
[2] Pacira Biosciences, Inc. Exparel.
[3] Exparel Prescribing Information.
[4] Getinge Group. Exparel: Transforming Pain Management.
[5] Decision Resources Group. CPT codes for Exparel.
[6] DrugPatentWatch.com. Exparel Patent Expiry.
[7] Law360. Exparel patent litigation.
[8] National Institute on Drug Abuse. Prescription Opioid Overdose Deaths.